HasselJC.KrippM.Al-BatranS.HofheinzR-D. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie. 2010;33(3):94-98.doi:10.1159/00027765620215799
MeloskyB.BurkesR.RaysonD.AlcindorT.ShearN.LacoutureM. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol. 2009;16(1):16-26.doi:10.3747/co.v16i1.36119229368
4.
LacoutureME.AnadkatMJ.BensadounR-Jet al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079-1095.doi:10.1007/s00520-011-1197-621630130
5.
YuZ.DeeEC.BachDQ.MostaghimiA.LeBoeufNR. Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center. JAMA Dermatol. 2020;156(10):1079.doi:10.1001/jamadermatol.2020.179532609305
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
